A bout a decade ago, the prevailing wisdom was that conventional risk factors explained only approximately half of the risk for a myocardial infarction or stroke. Consequently, efforts to identify novel risk factors were undertaken to improve cardiovascular risk prediction. The hypothesis that inflammation is a central contributor to atherothrombosis has stimulated sustained efforts to characterize the specific molecules and pathways that may be involved and to identify biomarkers in humans that enable detection of underlying inflammatory activation to improve cardiovascular risk prediction. Ridker et al 1 pioneered this work and reported that systemic low-grade inflammation assessed by measurements of the acute-phase reactant C-reactive protein is associated with future cardiovascular events in apparently healthy individuals. After this, B-type natriuretic peptide and its N-terminal fragment were highlighted to predict cardiovascular risk even in the general population. 2 Overall, C-reactive protein and the N-terminal fragment of B-type natriuretic peptide have most consistently improved risk estimates in specific populations. However, prediction metrics, which inform us about the predictive values beyond classic risk factors, have been less persuasive, and controversial data have been discussed. Recently, a new player entered the field of cardiovascular risk prediction. Troponin, assayed with a highly sensitive test that allows for reliable detection at very low concentrations, is associated with incident heart failure and mortality in the community. 3, 4 In this issue of Circulation, Saunders et al 5 report findings from the Atherosclerosis Risk in Communities (ARIC) Study extending this knowledge and indicating that troponin T concentrations are associated with incident coronary heart disease, mortality, and hospitalization for heart failure in the general population not formerly known to have cardiac disease. Even in the verylow-concentration range, troponin T is related to incident heart failure and mortality.
Article see p 1367
The advent of troponin testing in the emergency department setting constituted a milestone in the care of patients with chest pain, 6, 7 and troponin testing is now central to the diagnosis of acute myocardial infarction. In evaluation of patients with chest pain, application of biomarkers representing myocardial necrosis has been part of the diagnostic workup for years, in addition to ECG and clinical findings. The ability of cardiac troponin T and I to detect myocardial damage with high specificity led to a definition of myocardial infarction based on elevated troponin levels in addition to symptoms of ischemia and/or congruent imaging findings. 8 The currently used universal definition of myocardial infarction recommends the use of a robust and precise troponin assay with a coefficient of variation of Յ10% at the threshold concentration representing the 99th percentile of a reference population. This demand to optimize diagnosis of myocardial infarction according to the guidelines stimulated the development of newer, more sensitive troponin assays over the past few years. The introduction of such contemporary and highly sensitive troponin assays that meet the recommendations of the universal definition has enabled a significant improvement in the detection of troponin release, particularly early after an ischemic event. 9 Application of these assays in specific study populations as well as in unselected chest pain cohorts has proven to substantially facilitate early diagnosis of myocardial infarction. 10 -14 With the introduction of assays that allow for reliable troponin I detection at very low levels, the known strong potential of elevated troponin for risk stratification in patients with acute coronary syndrome 15, 16 can be translated to patients with stable disease. Omland et al 17 observed that even minor troponin elevations are associated with poorer outcome in patients with stable coronary artery disease.
The availability of different generations of troponin assays in respect to their improved sensitivity requires a welldefined classification system and nomenclature to adequately describe and address the individual assay. 18 One criterion that should be used for assay classification is the respective assay imprecision with information on the coefficient of variation, with Յ10% at the concentration representing the 99th percentile of a reference population used as diagnostic cutoff. Assays that provide such high precision should be characterized as contemporary sensitive assays. A second criterion should be the proportion of troponin detection in a general population, with highly sensitive troponin assays allowing measurements in at least half of the population. The next generation of super-sensitive troponin assays covers the complete reference range, with detectability in Ն95% of a general population. The Figure provides an overview of the proposed troponin nomenclature and potential clinical application; secondary prevention includes both stable and acute coronary syndrome.
Another aspect in the era of sensitive troponin assays merits consideration. Conventional troponin testing resulted in troponin-negative or -positive patients with clear therapeutic options. Use of sensitive or highly sensitive troponin assays provides much more information than a Boolean variable; their results must be interpreted as continuous values rather than as dichotomous information. Especially in settings other than diagnosis of myocardial infarction, few guidelines exist for interpretation of the measured troponin concentration. Accordingly, the established diagnostic troponin cutoff representing the 99th percentile of a reference population should only be applied in patients with suspected acute coronary syndrome, whereas in other clinical settings, individual thresholds or categories must be established.
In the current issue of Circulation, Saunders et al 5 now report the association between troponin T assayed with a highly sensitive test kit and incident heart failure, fatal and nonfatal coronary events, and overall mortality. Their study extends current knowledge described earlier from analyses of the Cardiovascular Health Study (which addresses the relationship between highly sensitive troponin T and incident heart failure as well as overall mortality in the elderly) 3 and the Dallas Heart Study (which describes the association between highly sensitive troponin T [detected in 25% of the population] 4 and overall mortality in younger individuals aged 35 to 65 years with a limited number of end points). The present findings of the ARIC Study now provide data on the middle-aged population with an age range of 54 to 74 years, resulting in detection of 66.5% of the individuals. Surprisingly, 7.4% of the ARIC population had troponin T levels Ͼ0.014 g/L, which should represent the 99th percentile of the general population. Although those individuals had been at highest risk for future events, those individuals with minimal elevated troponin T above the detection limit of 0.003 g/L were at increased risk for incident heart failure and overall mortality. Although the current data may result in improved cardiovascular risk prediction by an impressive net reclassification of 0.179 for overall coronary heart disease risk prediction, there is a need for better understanding of the manner in which troponin level predicts risk according to different decades among women and men separately. This is of particular importance because troponin concentrations, particularly in the low ranges, correlate moderately to strongly with age, and differ between men and women. Furthermore, we need to elaborate on whether the prediction metrics of a single troponin determination assayed with a highly sensitive test are similar or superior to a 3-marker score that had been defined in the European MONICA, Risk, Genetics, Archiving, and Monograph (MORGAM) consortium with the use of the FINRISK and Prospective Epidemiological Study of Myocardial Infarction (PRIME) cohorts in a derivation and validation approach. 19 Incorporation of a composite biomarker score including the noninterdependent variables troponin I (assayed with a contemporary sensitive assay), C-reactive protein, and the N-terminal fragment of B-type natriuretic peptide significantly improved risk assessment.
Far greater importance is now placed on the manner in which biomarkers might improve clinical decision making. In the present study, the most significant reclassification affected Ϸ17.9% of men destined for coronary heart disease risk during long-term follow-up. Potentially, some of the difference in net reclassification between men and women is attributable to the higher troponin detection and incident cardiac event rates in men. With this number of subjects in primary prevention settings, these proportions could portend significant resource implications if it were to be shown subsequently that treatment on the basis of this biomarker profile could improve outcomes, as has been claimed for C-reactive protein in the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. 20 Such studies are clearly warranted, given the long shadow cast by circulating troponin in middle-aged individuals, with an enduring association with long-term cardiovascular disease risk. In light of the strong association with prevalent structural heart disease and incident fatal and nonfatal cardiac events, it appears plausible that even the determination of very low troponin concentrations assayed with a highly sensitive troponin test might discriminate those individuals in the general population who could benefit from a primary prevention therapy irrespective of the presence of classic risk factors. As such, those medications addressing the renin-angiotensin mechanisms might be attractive candidates. Although the application of highly sensitive troponin testing in the population might make available a pathway to more personalized medication, much more remains to be done, including the performance of biomarker-guided trials.
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